SCHEMBL1110522

SCHEMBL1110522

CN(C)C(=O)c1cccc(CNC(=O)c2cccc3c(NS(=O)(=O)c4cc(Cl)cc(Cl)c4)cccc23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 1/20 0.46
▸ RAB9A P51151 1/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ NAMPT P43490 1/20 0.41
▸ ACLY P53396 5/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ ROCK2 O75116 2/20 0.39
▸ ROCK1 Q13464 1/20 0.39
▸ WDR5 P61964 1/20 0.38
▸ APEX1 P27695 1/20 0.38
▸ MT-CO2 P00403 1/20 0.38
▸ PLA2G1B P04054 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1110559 0.92 KCNA5 (0.46) KCNA5MEN1KMT2ANAMPTACLY
SCHEMBL1110326 0.89 KCNA5 (0.47) KCNA5RAB9AMEN1KMT2ANAMPT
SCHEMBL1110333 0.89 RAB9A (0.53) KCNA5RAB9AKMT2AACLYKDM4E
SCHEMBL1319106 0.88 CCR1 (0.47) KCNA5RAB9AMEN1KMT2ANAMPT
SCHEMBL1110477 0.88 KCNA5 (0.48) KCNA5RAB9AMEN1KMT2AACLY
SCHEMBL1110223 0.86 KMT2A (0.42) KCNA5MEN1KMT2ANAMPTACLY
SCHEMBL1319403 0.85 KCNA5 (0.61) KCNA5RAB9AMEN1KMT2AACLY
SCHEMBL13658796 0.84 KCNA5 (0.49) KCNA5RAB9AMEN1KMT2ANAMPT
SCHEMBL1110195 0.83 HPGD (0.53) KCNA5RAB9AKMT2AKDM4EALDH1A1
SCHEMBL1110215 0.82 KCNA5 (0.48) KCNA5MEN1KMT2ANAMPTACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 — — US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 — — US disclosed
EP-2279173-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-02 — — EP disclosed
WO-2009127723-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-22 — — WO disclosed
WO-2009127723-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 KCNA5 2527/4885RAB9A 2091/4885MEN1 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback